Decoding the MRI Evolution of Neuromuscular Choristoma to Desmoid-Type Fibromatosis

Neuromuscular choristoma (NMC) represents a rare developmental lesion involving the infiltration of mature skeletal muscle into peripheral nerves. While historically considered stable, clinical evidence shows these lesions can progress into aggressive desmoid-type fibromatosis (DTF). This transformation typically occurs within the same nerve territory. Understanding neuromuscular choristoma MRI progression is vital for early detection and avoiding iatrogenic triggers like unnecessary biopsies.

The Three Radiological Groups of NMC

A recent institutional study by Maldonado AA et al. analyzed sequential MR images to establish a classification framework. Consequently, researchers identified three distinct radiological stages that characterize the transition from a benign lesion to a more aggressive state.

• Group I (Classic NMC): These lesions exhibit typical features, including nerve enlargement and signal intensity similar to skeletal muscle.


• Group II (NMC Plus): This group acts as a transitional phase. It is characterized by atypical foci of low T1/T2 signal or moderate post-contrast enhancement.


• Group III (NMC-DTF): At this stage, a mass clearly extends beyond the epineurium, indicating established desmoid-type fibromatosis.

Risk Factors for Neuromuscular Choristoma MRI Progression

The study highlights that Group II patients face a significantly higher risk. In fact, 100% of patients in this group developed DTF within a mean period of 3 years. Furthermore, nearly 36% of Group I patients progressed to Group III over a longer mean interval of 6.2 years. These findings suggest that specific MRI changes serve as "red flags" for imminent tumor formation.

Clinical Implications and Surveillance

Radiologists and neurologists should adopt structured surveillance protocols. Because DTF is locally aggressive, early identification of Group II features allows for closer monitoring. Clinicians should also exercise extreme caution with biopsies, as trauma often triggers the rapid growth of DTF. Therefore, MRI remains the gold standard for non-invasive longitudinal management.

Frequently Asked Questions

What are the hallmark MRI features of Group II NMC?

Group II, or "NMC Plus," is identified by atypical foci of low T1/T2 signal intensity and moderate to significant post-contrast enhancement. These findings distinguish it from the classic stable NMC.

Why is serial MRI monitoring crucial for patients with NMC?

Serial MRI helps track the transition from benign choristoma to aggressive fibromatosis. Since Group II patients show a 100% progression rate within three years, frequent imaging is essential to adjust management before the mass extends beyond the nerve sheath.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Maldonado AA et al. Evolution of neuromuscular choristoma into neuromuscular choristoma-associated desmoid-type fibromatosis: evidence from serial MRI. J Neurosurg. 2026 Apr 17. doi: 10.3171/2025.11.JNS251747. PMID: 41996708.


2. Spinner RJ, et al. Expanding on MRI characteristics of neuromuscular choristoma: a single center retrospective review. Skeletal Radiol. 2025 May;54(5):1231-1240.


3. Lee CH, et al. Adult neuromuscular choristoma, a rare peripheral nerve pathology: illustrative case. J Neurosurg Case Lessons. 2024 Jan 29;7(5):CASE23594.